List view / Grid view
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Sanofi and Regeneron presented results of a Phase 3 study demonstrating the superiority of investigational sarilumab monotherapy versus adalimumab...
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A discount to the price of pertuzumab agreed with the company was an important factor in enabling NICE to overturn its earlier provisional decision...
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The BRIDGE study involved 245 men with osteoporosis randomised 2:1 to receive either 210 mg romosozumab or placebo subcutaneously once monthly for 1 year...
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The FDA granted priority review to the PKC412 (midostaurin) new drug application as treatment for acute myeloid leukaemia...
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Around three-quarters (74%) of people believe that a positive test for bacterial infection should be compulsory before being able to access antibiotics...
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
In more than 700 genotype 1-6 chronic HCV infected patients, 97.5% achieved sustained virologic response at 12 weeks, regardless of baseline viral load...
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
This conditional marketing authorisation is based on data from the Phase 2 portion of the pivotal JGDG trial and followed a positive recommendation from...
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Opdivo is the first and only Immuno-Oncology treatment proven in a Phase 3 trial to significantly extend overall survival for these patients...
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Genmab’s daratumumab (darazalex) will be investigated in a Phase III clinical study in combination with carfilzomib (kyprolis) and dexamethasone...
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
More than 75% of treatments in the Cancer Drugs Fund (CDF) which have been reappraised by the National Institute for Health and Care Excellence (NICE) have received positive recommendations for routine use in the NHS. NICE has been reappraising cancer drugs which had not been recommended in previous NICE guidance…
Linkam Scientific Instruments, announce the launch of the FDVS platform, a lyophilisation system to replicate large scale freeze drying processes...
15 November 2016 | By Niamh Louise Marriott, Digital Content Producer
We’re live at the Financial Times global pharmaceutical and biotechnology conference! Check this stream for live updates of the event…
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries...
11 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Prothena’s Phase 1b multiple ascending dose study of PRX002 trial found an acceptable safety and tolerability profile in patients with Parkinson’s disease...
11 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Bristol-Myers Squibb and Infinity will collaborate on a solid tumours trial to evaluate Bristol-Myers Squibb's Opdivo in combination with Infinity's...
